AR051842A1 - Derivados de oxadiazol como inhibidores de dgat - Google Patents

Derivados de oxadiazol como inhibidores de dgat

Info

Publication number
AR051842A1
AR051842A1 ARP050105216A ARP050105216A AR051842A1 AR 051842 A1 AR051842 A1 AR 051842A1 AR P050105216 A ARP050105216 A AR P050105216A AR P050105216 A ARP050105216 A AR P050105216A AR 051842 A1 AR051842 A1 AR 051842A1
Authority
AR
Argentina
Prior art keywords
group
independently selected
optionally substituted
cr42r43
cr52r53
Prior art date
Application number
ARP050105216A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35999598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR051842(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0427328A external-priority patent/GB0427328D0/en
Priority claimed from GB0507403A external-priority patent/GB0507403D0/en
Priority claimed from GB0520383A external-priority patent/GB0520383D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR051842A1 publication Critical patent/AR051842A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

La presente se refiere a derivados de oxadiasol como inhibidores de DGAT. También se describen procesos para preparar tales compuestos y su uso como inhibidores de DGAT, por ejemplo en el tratamiento de la obesidad. Reivindicacion 1: Un compuesto de formula (1) o su sal aceptable para uso farmacéutico o su profármaco, donde: R1 es un arilo opcionalmente sustituido o un grupo heteroarilo opcionalmente sustituido, donde lo sustituyentes opcionales son uno o más grupos seleccionados de un grupo -Za, un grupo -X2-(CR52R53)w-Za, un grupo -X2-(CR52R53)a-X3-Za, un grupo -(CR52R53)aX3-Za o un grupo funcional (el cual es diferente de un grupo -X2-(CR52R53)w-Za o de un grupo -X2-(CR52R53)a-X3-Za); Y e un enlace directo, o un grupo (CR40R41)s o - X6(CR40R41)t- donde cada R40 y R41 se seleccionan independientemente de H, alquilo C1-4, hidroxi, halo, haloalquilo C1-4, amino, ciano, alcoxi C1-4, haloalcoxi C1-4 o (alquilo C1-3)CONH-; s es un numero entero de 1 a 6 y t es un numero entero de 1 a 6, con la condicion de que el átomo X6 del grupo -X6(CR40R41)t- esté unido al grupo R2 y que un unico C hibridado sp3 no sea portador de dos o más enlaces a un heteroátomo a menos que el heteroátomo sea un halo; R2 es un arilo opcionalmente sustituido, un cicloalquilo opcionalmente sustituido o un grupo heterocíclico opcionalmente sustituido, donde los sustituyentes opcionales son uno o más grupos seleccionados de un grupo -Z, un grupo -X-(CR42R43)u-Z, un grupo -X-(CR42R43)v-X1-Z o un grupo -(CR42R43)vX1-Z o un grupo funcional (el cual es diferente de un grupo -X-(CR42R43)u-Z o un grupo -X-(CR42R43)v-X1-Z); donde Z y Za se seleccionan independientemente de un grupo hidrocarbilo o un grupo heterocíclico o su combinacion, donde el grupo Z y Za está opcionalmente sustituido en cualquier átomo disponible con uno o más grupos funcionales, o con un grupo -X7-(CR62R63)bR64; X, X1, X2, X3, X6 y X7 son grupos conectores seleccionados independientemente de -C(O)x-, -O-, -S(O)y-, - NR44, -C(O)R44-, -OC(O)NR44-, -CH=NO-, -NR44C(O)x-, -NR44CONR45-, -S(O)2NR44- o -NR44S(O)2-, donde x es un numero entero de 1 o 2, y es 0, 1 o 2, y R44 y R45 se seleccionan independientemente de H o alquilo C1-6, u y w se seleccionan independientemente de 0 o un numero entero de 1 a 6; v, a y b se seleccionan independientemente de un numero entero de 1 a 6; cada R42, R43, R52, R53, R62 y R63 se selecciona independientemente de H, alquilo C1-4, hidroxi, halo, haloalquilo C1-4, amino, ciano, alcoxi C1-4, haloalcoxi C1-4, alquilo (C1-3)CONH-, carboxi o un mimético de ácido carboxílico o bioisostero del mismo, y R64 es un grupo funcional.
ARP050105216A 2004-12-14 2005-12-13 Derivados de oxadiazol como inhibidores de dgat AR051842A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0427328A GB0427328D0 (en) 2004-12-14 2004-12-14 Chemical compounds
GB0507403A GB0507403D0 (en) 2005-04-13 2005-04-13 Chemical compounds
GB0520383A GB0520383D0 (en) 2005-10-07 2005-10-07 Chemical compounds

Publications (1)

Publication Number Publication Date
AR051842A1 true AR051842A1 (es) 2007-02-14

Family

ID=35999598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105216A AR051842A1 (es) 2004-12-14 2005-12-13 Derivados de oxadiazol como inhibidores de dgat

Country Status (15)

Country Link
US (2) US7795283B2 (es)
EP (1) EP1833806A1 (es)
JP (1) JP2008523133A (es)
KR (1) KR20070087096A (es)
AR (1) AR051842A1 (es)
AU (2) AU2005315430B2 (es)
BR (1) BRPI0519058A2 (es)
CA (1) CA2588162A1 (es)
IL (1) IL183279A0 (es)
MX (1) MX2007007101A (es)
NO (1) NO20072632L (es)
NZ (2) NZ555683A (es)
SA (1) SA05260407B1 (es)
TW (1) TW200633991A (es)
WO (1) WO2006064189A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090286791A1 (en) * 2001-11-27 2009-11-19 Takeda Pharmaceutical Company Limited Amide Compounds
US20040185559A1 (en) * 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
MX2007007101A (es) * 2004-12-14 2007-08-21 Astrazeneca Ab Derivados de oxadiazol como inhibidores de acil coa:diacilglicerol aciltransferasa.
BRPI0610850A2 (pt) * 2005-04-19 2008-12-02 Bayer Pharmaceuticals Corp derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
AR058562A1 (es) 2005-12-22 2008-02-13 Astrazeneca Ab Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
CA2651663A1 (en) * 2006-05-30 2007-12-06 Astrazeneca Ab Chemical compounds
US8084478B2 (en) * 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
US20090209602A1 (en) * 2006-06-06 2009-08-20 Roger John Butlin Chemical compounds
CN101460492A (zh) * 2006-06-08 2009-06-17 阿斯利康(瑞典)有限公司 苯并咪唑及其治疗糖尿病的用途
GB0611507D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) * 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
ES2397661T3 (es) * 2006-08-04 2013-03-08 Isis Pharmaceuticals, Inc. Composiciones y sus usos dirigidos a la diacilglicerol aciltransferasa 1
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
ATE554085T1 (de) * 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
KR20090098877A (ko) * 2006-12-11 2009-09-17 노파르티스 아게 심근 허혈의 예방 또는 치료 방법
CA2673076A1 (en) * 2006-12-21 2008-07-03 Abbott Laboratories Process for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane carboxylates
US20100093733A1 (en) * 2007-02-15 2010-04-15 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
GB0707662D0 (en) * 2007-04-20 2007-05-30 Astrazeneca Ab Chemical compounds
AU2008258560C1 (en) 2007-06-08 2014-04-10 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
CA2687912C (en) 2007-06-08 2015-11-03 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
PE20090362A1 (es) 2007-06-08 2009-04-04 Janssen Pharmaceutica Nv Derivados de piperidina/piperazina como moduladores de dgat
KR20100057068A (ko) * 2007-08-17 2010-05-28 아스트라제네카 아베 Ｄｇａｔ 억제제로서 옥사디아졸 유도체
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
KR20100099738A (ko) 2007-12-20 2010-09-13 아스트라제네카 아베 Ｄｇａｔ1 억제제로서의 카르바모일 화합물 190
EP2296659B1 (en) * 2008-06-05 2016-12-21 Janssen Pharmaceutica, N.V. Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
KR101124821B1 (ko) * 2008-08-27 2012-03-26 에스케이 텔레콤주식회사 Ｉｍｓ 서비스를 위한 ｐ-ｃｓｃｆ 설정 시스템 및 ｉｍｓ 서비스를 위한 ｐ-ｃｓｃｆ 설정 방법
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US20110224136A1 (en) * 2008-11-19 2011-09-15 Ting Pauline C Inhibitors of diacylglycerol acyltransferase
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
JP2012512860A (ja) 2008-12-19 2012-06-07 アストラゼネカ アクチボラグ １，３，４−オキサジアゾール誘導体および糖尿病を処置するそれらの使用
EP3366686B9 (en) 2009-03-20 2021-08-04 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof
MX2011011178A (es) 2009-04-21 2011-12-06 Astellas Pharma Inc Compuesto de diaciletilendiamina.
MX2011014018A (es) 2009-06-19 2012-02-22 Astrazeneca Ab Pirazincarboxamidas como inhibidores de dgati.
RU2012111354A (ru) 2009-08-26 2013-10-10 Санофи Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
SG183529A1 (en) 2010-03-30 2012-10-30 Novartis Ag Uses of dgat1 inhibitors
WO2011121350A1 (en) 2010-04-01 2011-10-06 Astrazeneca Ab 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors
TW201211027A (en) 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
ES2550312T3 (es) 2010-06-17 2015-11-06 Janssen Pharmaceutica Nv Antagonistas ciclohexil-azetidinilo de CCR2
WO2012044567A2 (en) * 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Imidazole derivatives
ES2525837T3 (es) 2010-12-01 2014-12-30 Janssen Pharmaceutica, N.V. Antagonistas de ccr2 de ciclohexilamino-4-piperidinil-acetamida sustituida en posición 4
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2014054053A1 (en) 2012-10-03 2014-04-10 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
JP2021512103A (ja) 2018-01-31 2021-05-13 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎａｍｐｔ阻害剤を含む抗体薬物複合体（ａｄｃｓ）
CN108658889B (zh) * 2018-05-11 2021-12-17 贵州医科大学 一种含萘环的1,2,4-噁二唑-芳基哌嗪型化合物及其制法和用途
JP7335849B2 (ja) * 2019-07-17 2023-08-30 信越化学工業株式会社 ジメチルシクロブタン環を有するジエステル化合物及びその製造方法、並びにそれから誘導されるジメチルシクロブタン化合物の製造方法
JP7410781B2 (ja) * 2019-07-17 2024-01-10 信越化学工業株式会社 ジメチルシクロブタノン化合物、ジメチルシクロブタン化合物及びそれらの製造方法
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
WO2023085931A1 (en) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatic organoids

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983731A (en) * 1989-03-17 1991-01-08 Nebraska Department Of Economic Development Separation and purification of sugar esters
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
US20030167483A1 (en) * 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
WO2000058491A1 (fr) 1999-03-25 2000-10-05 The Kitasato Institute Nouvelles substances kf-1040t4a, kf-1040t4b, kf-1040t5a et kf-1040t5b et leur procede de production
GB0021670D0 (en) * 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
IL160556A0 (en) * 2001-08-31 2004-07-25 Aventis Pharma Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
DE10223273A1 (de) 2002-05-24 2003-12-04 Aventis Pharma Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090286791A1 (en) 2001-11-27 2009-11-19 Takeda Pharmaceutical Company Limited Amide Compounds
FR2840301B1 (fr) 2002-05-29 2007-03-23 Sanofi Synthelabo Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
NZ537603A (en) 2002-07-12 2006-09-29 Sanofi Aventis Deutschland Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
NZ539952A (en) 2002-11-22 2008-05-30 Japan Tobacco Inc Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
WO2005046670A1 (en) 2003-11-11 2005-05-26 The Skinny Drink Company Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
JP2007519605A (ja) 2004-01-30 2007-07-19 日本たばこ産業株式会社 食欲抑制薬
WO2006004200A1 (ja) 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
ATE492542T1 (de) 2004-10-15 2011-01-15 Bayer Healthcare Llc Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
MX2007007101A (es) * 2004-12-14 2007-08-21 Astrazeneca Ab Derivados de oxadiazol como inhibidores de acil coa:diacilglicerol aciltransferasa.
US20090048258A1 (en) * 2005-02-01 2009-02-19 Masaki Ogino Amide Compound
MX2007009210A (es) 2005-02-07 2007-08-17 Hoffmann La Roche Inhibidores de diacilglicerol-aciltransferasa (dgat).
BRPI0610850A2 (pt) 2005-04-19 2008-12-02 Bayer Pharmaceuticals Corp derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
CN101171231A (zh) 2005-05-10 2008-04-30 霍夫曼-拉罗奇有限公司 二酰基甘油酰基转移酶抑制剂
WO2006134317A1 (en) 2005-06-11 2006-12-21 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
EP1912634A4 (en) 2005-07-29 2010-06-09 Bayer Healthcare Llc PREPARATION AND USE OF BIPHENYL AMINOACIDAL DERIVATIVES TO TREAT OBESITY
JP2007131584A (ja) 2005-11-11 2007-05-31 Sankyo Co Ltd 新規ベンゾオキサゾール誘導体
KR20080063865A (ko) 2005-11-28 2008-07-07 에프. 호프만-라 로슈 아게 다이아실글리세롤 아실전이효소(ｄｇａｔ)의 저해제
JP2007191471A (ja) 2005-12-21 2007-08-02 Sankyo Co Ltd ウレア誘導体を含有する医薬
AR058562A1 (es) 2005-12-22 2008-02-13 Astrazeneca Ab Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
EP2402317B1 (en) 2006-03-31 2013-07-03 Novartis AG DGAT inhibitor
WO2007137103A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2007137107A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
CA2651663A1 (en) 2006-05-30 2007-12-06 Astrazeneca Ab Chemical compounds
US8084478B2 (en) 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
US20090209602A1 (en) * 2006-06-06 2009-08-20 Roger John Butlin Chemical compounds
CN101460492A (zh) 2006-06-08 2009-06-17 阿斯利康(瑞典)有限公司 苯并咪唑及其治疗糖尿病的用途
GB0611507D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611506D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
US20120065196A1 (en) 2006-07-21 2012-03-15 Shuji Kitamura Amide compounds
US7569590B2 (en) * 2006-09-19 2009-08-04 Bristol-Myers Squibb Company Use of thianecarboxamides as dgat inhibitors
KR100811100B1 (ko) 2006-09-27 2008-03-06 한국생명공학연구원 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
KR100795462B1 (ko) 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
AU2007304365A1 (en) 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
ES2421326T3 (es) 2006-11-29 2013-08-30 Abbvie Inc. Inhibidores de la enzima diacilglicerol O-aciltransferasa de tipo 1
US20100093733A1 (en) 2007-02-15 2010-04-15 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
GB0707662D0 (en) 2007-04-20 2007-05-30 Astrazeneca Ab Chemical compounds
JP2010526781A (ja) 2007-04-30 2010-08-05 アボット・ラボラトリーズ ジアシルグリセロールｏ−アシル転移酵素１型酵素の阻害剤
WO2008134690A1 (en) 2007-04-30 2008-11-06 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
AU2008253118B2 (en) 2007-05-22 2013-11-21 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8058299B2 (en) * 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
PE20090362A1 (es) 2007-06-08 2009-04-04 Janssen Pharmaceutica Nv Derivados de piperidina/piperazina como moduladores de dgat
AU2008258560C1 (en) 2007-06-08 2014-04-10 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
CA2687912C (en) 2007-06-08 2015-11-03 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
WO2009011285A1 (ja) 2007-07-13 2009-01-22 Taisho Pharmaceutical Co., Ltd. ヘテロアリールベンゼン化合物
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
KR20100057068A (ko) 2007-08-17 2010-05-28 아스트라제네카 아베 Ｄｇａｔ 억제제로서 옥사디아졸 유도체
US20090076275A1 (en) 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009071483A1 (en) 2007-12-07 2009-06-11 Via Pharmaceuticals, Inc. 1- (indaz0l-5-yl) -ureas as diacylglycerol acyltransferase inhibitors
KR20100099738A (ko) 2007-12-20 2010-09-13 아스트라제네카 아베 Ｄｇａｔ1 억제제로서의 카르바모일 화합물 190
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
JP2012512860A (ja) * 2008-12-19 2012-06-07 アストラゼネカ アクチボラグ １，３，４−オキサジアゾール誘導体および糖尿病を処置するそれらの使用

Also Published As

Publication number Publication date
CA2588162A1 (en) 2006-06-22
MX2007007101A (es) 2007-08-21
AU2005315430B2 (en) 2010-05-27
US20080096874A1 (en) 2008-04-24
US20100317653A1 (en) 2010-12-16
KR20070087096A (ko) 2007-08-27
SA05260407B1 (ar) 2009-11-15
BRPI0519058A2 (pt) 2008-12-23
WO2006064189A1 (en) 2006-06-22
NZ555683A (en) 2010-09-30
NO20072632L (no) 2007-08-31
NZ587106A (en) 2012-03-30
TW200633991A (en) 2006-10-01
AU2010206031A1 (en) 2010-08-19
JP2008523133A (ja) 2008-07-03
AU2005315430A1 (en) 2006-06-22
IL183279A0 (en) 2007-09-20
US7795283B2 (en) 2010-09-14
EP1833806A1 (en) 2007-09-19

Similar Documents

Publication Publication Date Title
AR051842A1 (es) Derivados de oxadiazol como inhibidores de dgat
BRPI0810929B8 (pt) uso de um composto de fórmula 1
EA201101492A1 (ru) Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
PE20141827A1 (es) Inhibidores de proteinas quinasas
TN2009000012A1 (en) Amino-piperidine derivatives as cetp inhibitors
PE20090151A1 (es) Derivados de pirimidinona y metodos para su uso
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
IN2014DN06567A (es)
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
JO2741B1 (en) Spiro-cyclic nitroblast as protease inhibitors
ATE432259T1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
AR049138A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
ATE557014T1 (de) Neue substituierte indolin-2-on-derivate und ihre verwendung als p38-mitogenaktivierte kinasehemmer
EA201190119A1 (ru) ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38
PL2229356T3 (pl) 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
AR049487A1 (es) Compuestos de imidazol sustituidos
BRPI0411414A (pt) derivados de quinolil amida como antagonistas de cdr-5
AR062258A1 (es) Compuestos heterociclicos condensados de tieno-pirrol, composiciones farmaceuticas que los contienen y usos para el tratamiento de infecciones por hcv
BR112012014807A2 (pt) "compostos adequados para o tratamento de sinucleopatias"
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
GT200800200A (es) Derivados de benzimidazol
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
TW200800982A (en) Pyrazolopyridine derivatives as inhibitors of β-adrenergic receptor kinase 1
HK1133001A1 (en) Novel method for producing 4,4'-(1-methyl-1,2-ethanediyl)-bis-(2,6- piperazinedione)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal